NCT02713373 2022-10-06Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by SurgeryRoswell Park Cancer InstitutePhase 1/2 Completed45 enrolled 14 charts